SCLX vs. NVO

Last updated Jul 17, 2026

SCLX (Scilex Holding Company) and NVO (Novo Nordisk A/S) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 5 years, SCLX returned -47.30%/yr vs 4.76%/yr for NVO. At a 0.08 correlation, their price movements are largely independent.

Performance

SCLX vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Scilex Holding Company (SCLX) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SCLX achieves a 15.71% return, which is significantly higher than NVO's 2.36% return.

SCLX

• 1D: -4.66%
• 1M: 49.49%
• 6M: 23.18%
• YTD: 15.71%
• 1Y: 101.67%
• 3Y*: -59.52%
• 5Y*: -47.30%
• 10Y*: —

NVO

• 1D: -2.25%
• 1M: 15.62%
• 6M: -16.45%
• YTD: 2.36%
• 1Y: -19.33%
• 3Y*: -12.13%
• 5Y*: 4.76%
• 10Y*: 8.48%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SCLX vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SCLX Scilex Holding Company	15.71%	-18.25%	-79.10%	-48.87%	-60.26%	1.93%
NVO Novo Nordisk A/S	2.36%	-39.22%	-15.93%	54.84%	22.66%	65.01%

Correlation

The correlation between SCLX and NVO is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (3Y) Calculated over the trailing 3-year period	0.08
Correlation (5Y) Calculated over the trailing 5-year period	0.08
Correlation (All Time) Calculated using the full available price history since Mar 5, 2021	0.08

The correlation between SCLX and NVO shifts across timeframes, from 0.08 (3 years) to 0.20 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap SCLX : $74.64M NVO : $223.61B
EPS SCLX : -$35.56 NVO : DKK 27.42
PS Ratio SCLX : 3.29 NVO : 4.46
Total Revenue (TTM) SCLX : $30.25M NVO : DKK 327.80B
Gross Profit (TTM) SCLX : $18.07M NVO : DKK 268.30B
EBITDA (TTM) SCLX : -$352.83M NVO : DKK 181.54B

Return for Risk

SCLX vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SCLX

SCLX Risk / Return Rank: 72
SCLX Sharpe Ratio Rank: 71
SCLX Sortino Ratio Rank: 79
SCLX Omega Ratio Rank: 76
SCLX Calmar Ratio Rank: 70
SCLX Martin Ratio Rank: 63

NVO

NVO Risk / Return Rank: 29
NVO Sharpe Ratio Rank: 27
NVO Sortino Ratio Rank: 29
NVO Omega Ratio Rank: 28
NVO Calmar Ratio Rank: 31
NVO Martin Ratio Rank: 32

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SCLX vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Scilex Holding Company (SCLX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SCLX	NVO	Difference
Sharpe ratio: Return per unit of total volatility	0.81	-0.38	+1.18
Sortino ratio: Return per unit of downside risk	2.02	-0.19	+2.21
Omega ratio: Gain probability vs. loss probability	1.24	0.97	+0.26
Calmar ratio: Return relative to maximum drawdown	1.27	-0.39	+1.67
Martin ratio: Return relative to average drawdown	1.82	-0.61	+2.43

SCLX vs. NVO - Sharpe Ratio Comparison

The current SCLX Sharpe Ratio is 0.81, which is higher than the NVO Sharpe Ratio of -0.38. The chart below compares the historical Sharpe Ratios of SCLX and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SCLX vs. NVO - Drawdown Comparison

The maximum SCLX drawdown since its inception was -99.23%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for SCLX and NVO.

Drawdown Indicators

	SCLX	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-99.23%	-74.70%	-24.53%
Max Drawdown (1Y) Largest decline over 1 year	-80.27%	-49.17%	-31.10%
Max Drawdown (3Y) Largest decline over 3 years	-98.19%	-74.70%	-23.49%
Max Drawdown (5Y) Largest decline over 5 years	-99.23%	-74.70%	-24.53%
Max Drawdown (10Y) Largest decline over 10 years	—	-74.70%	—
Current Drawdown Current decline from peak	-97.27%	-63.44%	-33.83%
Average Drawdown Average peak-to-trough decline	-57.59%	-17.88%	-39.71%
Ulcer Index Depth and duration of drawdowns from previous peaks	56.13%	31.70%	+24.43%

Volatility

SCLX vs. NVO - Volatility Comparison

Scilex Holding Company (SCLX) has a higher volatility of 36.42% compared to Novo Nordisk A/S (NVO) at 9.27%. This indicates that SCLX's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SCLX	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	36.42%	9.27%	+27.15%
Volatility (6M) Calculated over the trailing 6-month period	77.65%	37.52%	+40.13%
Volatility (1Y) Calculated over the trailing 1-year period	126.83%	51.76%	+75.07%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	113.27%	38.56%	+74.71%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	109.29%	32.61%	+76.68%

Dividends

SCLX vs. NVO - Dividend Comparison

SCLX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.58%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NVO Novo Nordisk A/S	3.58%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%
SCLX Scilex Holding Company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both SCLX and NVO in my portfolio?

SCLX and NVO have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SCLX or NVO?

SCLX has higher volatility (36.42%) compared to NVO (9.27%). In terms of maximum drawdown, SCLX dropped -99.23% vs NVO's -74.70%.

Which has better risk-adjusted returns?

SCLX currently has the higher Sharpe Ratio (0.81 vs -0.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.